Amvuttra
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Amvuttra in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Amvuttra.
44
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Amvuttra
The drug has been authorised to treat both wild-type and hereditary forms of the disease
The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease
Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide
The committee has recommended the drug for both wild type and hereditary ATTR-CM
Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy
The company said it will be proceeding with regulatory filings for the therapy later this year
Hereditary ATTR and wild-type ATTR are responsible for an estimated 350,000 cases globally
Amvuttra is given every three months, compared to every few weeks with existing therapies
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology